At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? | Zendy

Magnus Johannesson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

Author(s) -

Magnus Johannesson

Publication year - 2001

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.2000.2484

Subject(s) - medicine , drug , primary prevention , cholesterol , coronary heart disease , risk factor , secondary prevention , cholesterol lowering , coronary disease , intensive care medicine , cardiology , pharmacology , disease

The entire risk factor profile should be taken into account when considering initiating cholesterol lowering drug treatment. Recent treatment guidelines are therefore based on the absolute risk of coronary heart disease. We estimated at what coronary risk it is cost-effective to initiate cholesterol lowering drug treatment in primary prevention for men and women of different ages in Sweden.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research